InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| General and administrative | $1.3M-2.5% | $1.3M+48.4% | $899K+11.3% | $807K-28.0% | $1.1M |
| Research and development | $83K-77.8% | $373K-28.8% | $524K-35.2% | $809K+8.2% | $748K |
| Stock-based compensation | $1.0M-60.1% | $2.6M+292.9% | $664K+156.2% | $259K-15.8% | $308K |
| Total operating expenses | $2.4M-43.8% | $4.3M+106.8% | $2.1M-46.6% | $3.9M+79.6% | $2.2M |
| Interest expense, net | $4K+4.3% | $4K+0.0% | $4K | — | — |
| Net loss | -$2.4M+43.8% | -$4.3M-106.7% | -$2.1M+46.6% | -$3.9M-79.6% | -$2.2M |
| Net loss per share, basic | -$0.13+45.8% | -$0.24-100.0% | -$0.12+52.0% | -$0.25-400.0% | -$0.05 |
| Net loss per share, diluted | -$0.13+45.8% | -$0.24-100.0% | -$0.12+52.0% | -$0.25 | — |
| Weighted average number of common shares outstanding during the period- basic | $18.6M+3.5% | $17.9M+3.4% | $17.4M+11.3% | $15.6M-62.2% | $41.2M |
| Weighted average number of common shares outstanding during the period- diluted | $18.6M+3.5% | $17.9M+3.4% | $17.4M+11.3% | $15.6M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
RetinalGenix announces key management changes
RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases